Major Neurotransmitter Systems

A neurotransmitter system is defined by more than the identity of a molecule. It is the entire biological apparatus built around that molecule: the enzymes that synthesize it, the vesicular transporter that packages it, the release machinery that exocytoses it, the postsynaptic receptors (both ionotropic, for millisecond signaling, and metabotropic, for second-to-minute modulation) that detect it, and the mechanism — reuptake or enzymatic degradation — that terminates its action. Two neurons using the same transmitter can behave completely differently depending on which of these components they express, and a single transmitter often plays multiple, even opposite, functional roles depending on receptor subtype and target circuit. Neuroscientists broadly separate transmitter systems into two functional categories. Fast point-to-point transmitters — glutamate and GABA, plus glycine — mediate the millisecond-to-millisecond flow of information through defined synaptic circuits; they are released at discrete synapses and act mainly through ionotropic receptors that directly gate ion channels. Neuromodulatory systems — acetylcholine, dopamine, serotonin, norepinephrine, and histamine — arise from small numbers of neurons in restricted brainstem or basal forebrain nuclei whose axons diffusely innervate vast territories of cortex, striatum, and spinal cord. These systems act mostly (though not exclusively) through metabotropic G-protein-coupled receptors, producing effects that unfold over hundreds of milliseconds to minutes and that adjust the gain, timing, or plasticity of the fast circuits rather than carrying specific sensory or motor content themselves. A useful organizing principle, Dale's principle, states that a given neuron releases the same set of transmitters at all of its synaptic terminals (with the modern refinement that neurons commonly co-release a small-molecule transmitter alongside one or more neuropeptides). Because receptor expression, not transmitter identity, determines the postsynaptic effect, the same released glutamate molecule can depolarize one neuron through an AMPA receptor and trigger a slow metabotropic cascade in another through an mGluR — this receptor-level flexibility, layered on top of a small transmitter vocabulary, is what gives the nervous system its combinatorial power.

Glutamate is the principal excitatory transmitter of the mammalian central nervous system, used at an estimated 80–90% of central synapses. It is synthesized locally in nerve terminals from glutamine (supplied by neighboring astrocytes via the glutamate–glutamine cycle) or from the Krebs-cycle intermediate α-ketoglutarate, packaged into synaptic vesicles by vesicular glutamate transporters (VGLUT1/2/3), and released by calcium-triggered exocytosis. Postsynaptically it acts on ionotropic AMPA receptors (fast, millisecond depolarization), NMDA receptors (voltage- and ligand-gated, calcium-permeable, central to synaptic plasticity), kainate receptors, and metabotropic mGluRs (slow modulation via Gq or Gi pathways). Its action is terminated not by an enzyme but by rapid reuptake into astrocytes and neurons via excitatory amino acid transporters (EAATs); astrocytes convert glutamate to glutamine via glutamine synthetase and return it to neurons, closing the glutamate–glutamine cycle. Excess extracellular glutamate is neurotoxic (excitotoxicity), so this reuptake step is not a metabolic detail but a life-or-death safety mechanism, relevant to stroke and ALS pathology.

GABA (γ-aminobutyric acid) is the principal inhibitory transmitter, used at most of the remaining central synapses not using glutamate or glycine. It is synthesized from glutamate in a single step by glutamic acid decarboxylase (GAD, requiring pyridoxal phosphate, vitamin B6, as cofactor) — a direct metabolic link meaning the brain's main excitatory and inhibitory transmitters are one enzymatic step apart. GABA is packaged by the vesicular GABA transporter (VGAT) and acts on ionotropic GABA_A receptors (chloride channels producing fast hyperpolarizing or shunting inhibition, the target of benzodiazepines and barbiturates) and metabotropic GABA_B receptors (Gi-coupled, opening potassium channels for slow inhibition). Termination is by reuptake via GABA transporters (GAT1) into neurons and glia, followed by degradation via GABA transaminase, feeding back into the Krebs cycle.

Acetylcholine (ACh) is synthesized in a single step from choline and acetyl-CoA by choline acetyltransferase (ChAT), the definitive marker enzyme of cholinergic neurons. It is packaged by the vesicular acetylcholine transporter (VAChT) and acts on two entirely distinct receptor families: ionotropic nicotinic receptors (fast cation channels, found at the neuromuscular junction and throughout the CNS) and metabotropic muscarinic receptors (five subtypes, M1–M5, coupled to Gq or Gi). Uniquely among major transmitters, ACh is cleared not by reuptake but by rapid enzymatic hydrolysis: acetylcholinesterase (AChE) sits in the synaptic cleft and breaks ACh into choline and acetate within about a millisecond, among the fastest enzymatic reactions known. Choline is then recaptured by a high-affinity transporter for resynthesis. Two major cholinergic systems project centrally: the basal forebrain nuclei (including the nucleus basalis of Meynert), critical for cortical arousal and memory, and brainstem pedunculopontine/laterodorsal tegmental nuclei, involved in REM sleep and arousal.

Dopamine is synthesized from the amino acid tyrosine through a two-step pathway: tyrosine hydroxylase (the rate-limiting enzyme) converts tyrosine to L-DOPA, and aromatic amino acid decarboxylase converts L-DOPA to dopamine. It is packaged by the vesicular monoamine transporter (VMAT2) — shared with norepinephrine, serotonin, and histamine — and released at both classical synapses and, importantly, at non-synaptic varicosities for diffuse volume transmission. Dopamine acts exclusively through metabotropic receptors: D1-like (D1, D5; Gs-coupled, excitatory) and D2-like (D2, D3, D4; Gi-coupled, inhibitory, and functioning as presynaptic autoreceptors that limit further release). Termination is by reuptake via the dopamine transporter (DAT) — the molecular target of cocaine and amphetamine — and metabolism by monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT). Four major dopaminergic pathways originate almost entirely from two adjacent midbrain nuclei:

Serotonin (5-hydroxytryptamine, 5-HT) is synthesized from the amino acid tryptophan by tryptophan hydroxylase (rate-limiting, requiring tryptophan to be obtained from the diet) followed by decarboxylation. It is packaged by VMAT2 and released from neurons whose cell bodies cluster almost entirely in the raphe nuclei of the brainstem, from which axons diffusely innervate essentially the entire brain and spinal cord. Serotonin has the most receptor diversity of any transmitter — at least fourteen subtypes (5-HT1 through 5-HT7, several with further subdivisions), nearly all metabotropic except the ionotropic 5-HT3 receptor, a ligand-gated cation channel notably targeted by anti-nausea drugs. Termination is via the serotonin transporter (SERT), the target of SSRIs (selective serotonin reuptake inhibitors), and metabolism by MAO. Serotonergic tone from the raphe modulates mood, sleep-wake cycles, appetite, and pain processing.

Norepinephrine (NE) is synthesized from dopamine by an additional enzymatic step, dopamine β-hydroxylase, occurring inside the synaptic vesicle itself. Nearly all central noradrenergic neurons originate in the locus coeruleus, a tiny brainstem nucleus of only tens of thousands of neurons per side that nonetheless projects to virtually every region of the CNS. NE acts on metabotropic α1, α2, and β adrenergic receptors; α2 receptors function as presynaptic autoreceptors. Termination is via the norepinephrine transporter (NET) and MAO/COMT metabolism. The locus coeruleus fires tonically at a low rate during quiet wakefulness and in high-frequency bursts in response to salient or threatening stimuli, making norepinephrine central to arousal, vigilance, and the fight-or-flight response.

The foundational proof that neurons communicate chemically, not purely electrically, came from Otto Loewi's 1921 experiment on isolated frog hearts, an idea he reported coming to him in a dream. Loewi dissected out two beating frog hearts, keeping each bathed in its own saline reservoir, and electrically stimulated the vagus nerve still attached to the first heart, which slowed its beat as expected. He then transferred the perfusion fluid from around the first (stimulated) heart onto the second, previously unstimulated, heart — and the second heart also slowed. Because the second heart had no nerve stimulated, the only possible explanation was that the first heart's vagus nerve had released a chemical substance into the fluid, which then acted on the second heart. Loewi called the substance "Vagusstoff"; it was later identified as acetylcholine, and Loewi shared the 1936 Nobel Prize in Physiology or Medicine with Henry Dale for this work. This experiment is the founding demonstration of chemical synaptic transmission, and it established the logical template — release, transfer, and biological action independent of the original stimulus — still used to identify neurotransmitter candidates today.

Henry Dale's parallel work on acetylcholine at the neuromuscular junction and in the autonomic nervous system established what became known as Dale's principle and clarified the distinction between nicotinic and muscarinic actions, using nicotine and muscarine as the pharmacological tools that gave these receptor classes their names. Dale showed that the effects of injected acetylcholine mimicked parasympathetic nerve stimulation (a "muscarinic" action, blocked by atropine) at low doses and ganglionic/skeletal-muscle stimulation (a "nicotinic" action) at higher doses, revealing that one transmitter could produce pharmacologically distinguishable effects through distinct receptor populations — a principle that generalizes directly to the multiple receptor subtypes now known for dopamine, serotonin, and every other major transmitter. For dopamine specifically, the decisive evidence linking a single transmitter pathway to a specific disease came from Arvid Carlsson's work in the late 1950s. Carlsson showed that reserpine, a drug that depletes vesicular monoamine stores, produced profound behavioral immobility (akinesia) in rabbits closely resembling Parkinsonian symptoms; critically, administering L-DOPA (the dopamine precursor, capable of crossing the blood-brain barrier when dopamine itself cannot) reversed this immobility within minutes, while restoring measurable brain dopamine levels. This causal chain — deplete dopamine, produce Parkinsonian signs; restore dopamine, restore movement — directly established dopamine's specific role in motor control, distinguishing it from norepinephrine and serotonin (whose depletion did not reverse the akinesia the same way), and it directly motivated the clinical introduction of L-DOPA therapy for human Parkinson disease in the late 1960s. Carlsson received the 2000 Nobel Prize in Physiology or Medicine for this work, shared with Paul Greengard and Eric Kandel for elucidating signal transduction in the nervous system. Complementary anatomical evidence came from histofluorescence mapping by Annica Dahlström and Kjell Fuxe (1964), who used the Falck-Hillarp formaldehyde-induced fluorescence technique to visualize catecholamine- and serotonin-containing neurons directly in brain sections for the first time. Their systematic atlas revealed that dopamine, norepinephrine, and serotonin neurons each cluster in small, discrete, numbered brainstem nuclei (the "A" groups for catecholamines, "B" groups for serotonin) sending long, diffusely branching axons throughout the brain — a fundamentally different anatomical organization from the point-to-point wiring of glutamatergic and GABAergic circuits, and the direct empirical basis for the modern concept of "neuromodulatory systems."

Example 1 — Reasoning through a pharmacological block. A researcher applies atropine (a competitive muscarinic antagonist) to a slice of hippocampus and records from a pyramidal neuron while stimulating a cholinergic afferent. Before atropine, stimulation produces a slow depolarization lasting ~200 ms; after atropine, electrical stimulation of the same fiber still produces a fast, 2–3 ms depolarizing response, though smaller. Question: what does this reveal about the postsynaptic receptor population, and is the finding consistent with Dale's principle? Reasoning: acetylcholine acting through muscarinic (metabotropic, Gq/Gi-coupled) receptors would be blocked by atropine, eliminating slow, second-messenger-mediated depolarization — consistent with the loss of the 200 ms component. The surviving fast component, insensitive to atropine, indicates a second, ionotropic receptor population — nicotinic receptors — coexists at the same terminal. This is fully consistent with Dale's principle: the same cholinergic neuron releases one transmitter, acetylcholine, but that single transmitter acts on two pharmacologically and kinetically distinct receptor classes expressed postsynaptically, producing a fast component and a slow component from a single release event. The experiment does not imply co-release of two transmitters; it demonstrates receptor heterogeneity downstream of one transmitter.

Example 2 — Quantitative reasoning about clearance kinetics. Acetylcholinesterase hydrolyzes acetylcholine with a catalytic turnover number (kcat) of roughly 10⁴ molecules per second per enzyme molecule, among the fastest known enzymes; a typical synaptic vesicle contains on the order of 10⁴ molecules of ACh. Estimate, to an order of magnitude, how long it would take a single AChE molecule to clear one vesicle's worth of released acetylcholine, and explain why this kinetic property is functionally essential at the neuromuscular junction. Reasoning: time ≈ (molecules to clear) / (molecules cleared per second) = 10⁴ / 10⁴ ≈ 1 second for a single enzyme molecule — but the neuromuscular junction is densely packed with AChE (roughly 2,600 enzyme sites per square micrometer of postsynaptic membrane), so in practice thousands of enzyme molecules act in parallel, clearing the synaptic cleft in roughly 1 millisecond. This near-instantaneous termination is functionally essential because skeletal muscle must be able to follow rapid trains of motor neuron firing (tens of Hz) with a distinct, well-timed twitch for each action potential; if ACh lingered, successive endplate potentials would summate uncontrollably, producing sustained depolarization and functional blockade — exactly what happens pathologically when AChE is inhibited by organophosphate nerve agents or pesticides, causing a cholinergic crisis of continuous muscle fiber depolarization, fasciculation, and eventually depolarization block and paralysis.

Otto Loewi (1873–1961) trained as a physician in Strasbourg and Munich before turning to pharmacology, eventually settling at the University of Graz in Austria. He worked for years on questions of cardiac and autonomic physiology in relative obscurity before his famous 1921 dream — he reportedly woke at 3 a.m., scribbled an experimental design, fell back asleep, and could not read his own notes the next morning, so he had to wait for the dream to recur the following night before performing the experiment exactly as planned. Loewi's career was upended when Austria was annexed by Nazi Germany in 1938; he was arrested, forced to surrender his Nobel Prize money to secure his family's emigration, and spent his final decades in the United States, continuing to publish and teach at New York University until his death.

Nearly every widely used neuropsychiatric and neurological drug class is a direct intervention at some step of a transmitter system's synthesis-release-receptor-clearance cycle. Parkinson disease is treated with L-DOPA (bypassing the rate-limiting tyrosine hydroxylase step, since dopamine itself cannot cross the blood-brain barrier) and with dopamine agonists or MAO-B inhibitors that slow dopamine breakdown. Depression and anxiety are treated with SSRIs and SNRIs that block SERT and NET reuptake transporters, and with MAO inhibitors that block monoamine breakdown, though the multi-week delay before clinical benefit points to slower receptor-adaptation mechanisms beyond simple transporter blockade. Myasthenia gravis, an autoimmune disease attacking nicotinic acetylcholine receptors at the neuromuscular junction, is treated with acetylcholinesterase inhibitors (pyridostigmine) that prolong the action of the remaining available acetylcholine. Epilepsy is managed with drugs that enhance GABA_A receptor function (benzodiazepines, barbiturates) or block glutamatergic excitation, directly shifting the excitatory-inhibitory balance introduced above. Schizophrenia antipsychotics act principally as D2 receptor antagonists, consistent with the dopamine hypothesis of psychosis, while newer atypical agents add serotonergic (5-HT2A) antagonism. Nerve agent and pesticide poisoning (organophosphates) work by irreversibly inhibiting acetylcholinesterase, and the antidote, atropine, works by blocking the resulting excess acetylcholine at muscarinic receptors — a direct clinical application of Dale's original nicotinic/muscarinic distinction. In agriculture and public health, understanding insect-specific differences in acetylcholinesterase and nicotinic receptor pharmacology underlies the design of selective insecticides that spare mammalian nervous systems, and ongoing work on Synaptic Plasticity and glutamate receptor trafficking informs both learning-and-memory research and the search for new anti-excitotoxic stroke therapies.

Ask the tutor: How do co-released neuropeptides modify or prolong the action of a classical small-molecule transmitter at the same synapse?